Chiang Mai University, Faculty of Medicine, Chiang Mai, Thailand.
Chiang Mai University, Department of Emergency Medicine, Faculty of Medicine, Chiang Mai, Thailand.
West J Emerg Med. 2021 Jul 19;22(4):834-841. doi: 10.5811/westjem.2021.2.49590.
The benefit of medications used in out-of-hospital, shock-refractory cardiac arrest remains controversial. This study aims to compare the treatment outcomes of medications for out-of-hospital, shock-refractory ventricular fibrillation (VF) or pulseless ventricular tachycardia (pVT).
The inclusion criteria were randomized controlled trials of participants older than eight years old who had atraumatic, out-of-hospital, shock-refractory VF/pVT in which at least one studied group received a medication. We conducted a database search on October 28, 2019, that included PubMed, Scopus, Web of Science, CINAHL Complete, and Cochrane CENTRAL. Citations of relevant meta-analyses were also searched. We performed frequentist network meta-analysis (NMA) to combine the comparisons. The outcomes were analyzed by using odds ratios (OR) and compared to placebo. The primary outcome was survival to hospital discharge. The secondary outcomes included the return of spontaneous circulation (ROSC), survival to hospital admission, and the neurological outcome at discharge. We ranked all outcomes using surface under the cumulative ranking score.
We included 18 studies with 6,582 participants. The NMA of 20 comparisons included 12 medications and placebo. Only norepinephrine showed a significant increase of ROSC (OR = 8.91, 95% confidence interval [CI], 1.88-42.29). Amiodarone significantly improved survival to hospital admission (OR = 1.53, 95% CI, 1.01-2.32). The ROSC and survival-to-hospital admission data were significantly heterogeneous with the I2 of 55.1% and 59.1%, respectively. This NMA satisfied the assumption of transitivity.
No medication was associated with improved survival to hospital discharge from out-of-hospital, shock-refractory cardiac arrest. For the secondary outcomes, norepinephrine was associated with improved ROSC and amiodarone was associated with an increased likelihood of survival to hospital admission in the NMA.
在院外、无反应性心搏骤停中使用药物的益处仍存在争议。本研究旨在比较院外、无反应性室颤(VF)或无脉性室性心动过速(pVT)的药物治疗结局。
纳入标准为年龄大于 8 岁、无创伤性、院外、无反应性 VF/pVT 患者的随机对照试验,其中至少有一组研究对象接受了一种药物治疗。我们于 2019 年 10 月 28 日在 PubMed、Scopus、Web of Science、CINAHL Complete 和 Cochrane CENTRAL 数据库进行了检索,并检索了相关荟萃分析的参考文献。我们进行了频率网络荟萃分析(NMA)来合并比较。使用比值比(OR)来分析结局,并与安慰剂进行比较。主要结局为出院时存活。次要结局包括自主循环恢复(ROSC)、入院时存活和出院时的神经结局。我们使用累积排序曲线下面积来对所有结局进行排序。
我们纳入了 18 项研究,共 6582 名患者。20 项比较的 NMA 纳入了 12 种药物和安慰剂。只有去甲肾上腺素显示 ROSC 显著增加(OR=8.91,95%置信区间[CI],1.88-42.29)。胺碘酮显著提高了入院存活率(OR=1.53,95%CI,1.01-2.32)。ROSC 和入院存活率数据的异质性较大,分别为 55.1%和 59.1%。此 NMA 满足可传递性假设。
在院外、无反应性心搏骤停中,没有药物与出院时存活相关。对于次要结局,NMA 显示去甲肾上腺素与 ROSC 改善相关,胺碘酮与入院存活率提高相关。